Sorafenib

別名:NSC-724772,BAY 43-9006

Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Sorafenib化学構造

CAS No. 284461-73-0

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 29500 国内在庫あり
JPY 22000 国内在庫あり
JPY 40500 国内在庫あり
JPY 74500 国内在庫あり
JPY 145500 国内在庫あり
JPY 220500 国内在庫あり

代表番号: 045-509-1970|電子メール:sales@selleck.co.jp
よく尋ねられる質問

製品安全説明書

現在のバッチを見る: 純度: 99.89%
99.89

Sorafenib関連製品

シグナル伝達経路

Raf阻害剤の選択性比較

阻害剤 Citation EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR その他
Saracatinib (AZD0530) 299 c-Src,c-YES,LCK
Canertinib (CI-1033) 48
AG-490 132 JAK2 (V617F)
CP-724714 108
WZ4002 34
Sapitinib (AZD8931) 48
CUDC-101 23 HDAC,HDAC1,HDAC6
AG-1478 97
PD153035 HCl 17
Pelitinib (EKB-569) 11 Src,MEK/ERK,Raf
AEE788 (NVP-AEE788) 13 c-Abl,FLT1,c-Fms
AC480 (BMS-599626) 10
AP26113-analog (ALK-IN-1) 4 ALK,IGF1R,INSR
WZ3146 2
Allitinib tosylate 16
Rociletinib (CO-1686) 36
Varlitinib 8
Icotinib (BPI-2009H) 9
TAK-285 4 MEK1,Aurora B,LCK
WHI-P154 11 Src,VEGFR,JAK3
Daphnetin 4 PKA,PKC
PD168393 6
CNX-2006 2
Tyrphostin 9 1 PDGFR
AG-18 1
Icotinib Hydrochloride 0
HS-10296 hydrochloride 0
MTX-531 0 PI3Kα
Avitinib maleate 0 BTK
limertinib 0
AG 825 0 PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 0
AST-1306 0
ErbB2 inhibitor 0
Tuxobertinib (BDTX-189) 2 RIPK2,BLK
Epertinib hydrochloride 0
JND3229 0 EGFR C797S
BI-4020 1
Tyrphostin AG-528 0
AG 556 0
Canertinib dihydrochloride 8
EGFR Inhibitor 3 Microtubules
SU5214 0 VEGFR2
RG 13022 0
TQB3804 0
zipalertinib (TAS6417) 3 TXK,BMX
Pyrotinib dimaleate 4
PD153035 14
AG 494 0
AG 555 0
Theliatinib (HMPL-309) 0
Avitinib (Abivertinib) 2 JAK3,BTK
Lazertinib 7 Del19,L85R
Lifirafenib (BGB-283) 6 WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816) 6
Zorifertinib (AZD3759) 6
CL-387785 (EKI-785) 5
Poziotinib 34
AZ5104 4 ACK1,BLK,BRK
AV-412 free base 0
HER2-Inhibitor-1 1
WZ8040 2
Genistein 32 topo II
Rezivertinib 0
BDTX-1535 0
Falnidamol 0
BLU-945 0
(S)-Sunvozertinib ((S)-DZD9008) 1
Licochalcone D 0 NF-κB,PARP,Caspase
Alflutinib (Furmonertinib) mesylate 2 CYP3A4
(Rac)-JBJ-04-125-02 0
Tyrphostin AG30 (AG30) 0
AG-1557 0
AG99 0
MTX-211 2 PI3K
RG14620 0 ABCG2
Almonertinib (HS-10296) 2
Cyasterone 1
Norcantharidin 3 c-Met
Naquotinib(ASP8273) 1
EAI045 2
Olmutinib (BI 1482694) 5 BTK
Butein 2
Chrysophanic Acid 3 mTOR
EGCG ((-)-Epigallocatechin Gallate) 41 DNMT,telomerase,FASN
もっと見る
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
OS-RC-2 Growth Inhibition Assay IC50=9.11243 μM SANGER
LC-1F Growth Inhibition Assay IC50=9.10834 μM SANGER
TE-10 Growth Inhibition Assay IC50=8.76353 μM SANGER
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
もっとクリックする
6 nM 15 nM 20 nM 22 nM 38 nM
In Vitro
In vitro Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]
Kinase Assay Biochemical assays
Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞実験 細胞株 MDA-MB-231, and HAoSMC
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 72 hours
実験の流れ

Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.

実験結果図 Methods Biomarkers 結果図 PMID
Western blot LC3-I / LC-3II / ATG5 p-STAT3 / STAT3 / Mcl-1 β-catenin / Survivin / Mcl-1 / PTMA pERK / ERK p-PKM2(y105) / PMK2 / Caspase-9 RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204) Cyclin D1 23392173
Growth inhibition assay Cell viability 26039995
Immunofluorescence p65 cytochrome c 22286758
ELISA TGF-beta / CD206 Caspase-9 / Caspase-3 26158762
In Vivo
In Vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]
動物実験 動物モデル Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
投与量 ~60 mg/kg
投与経路 Orally once daily
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05068752 Recruiting
Pancreas Cancer
HonorHealth Research Institute|Bayer|Genentech Inc.
October 28 2021 Phase 2
NCT04763408 Active not recruiting
Carcinoma Hepatocellular
Eisai Inc.
April 9 2021 --

化学情報

分子量 464.82 化学式

C21H16ClF3N4O3

CAS No. 284461-73-0 SDF Download Sorafenib SDFをダウンロードする
Smiles CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
保管

In vitro
Batch:

DMSO : 93 mg/mL ( (200.07 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機
Clear solution
5%DMSO Corn oil
5.0mg/ml (10.76mM) Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店